April 1, 2015

Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer’s Disease

NEWARK, N.J., March 17, 2015 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP) today announced secondary and exploratory endpoint results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer’s disease (AD). Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCe). The Company is approaching the treatment of Alzheimer’s disease through the activation of PKCe. In animal models of Alzheimer’s disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration.

Read Full Article

Print Friendly, PDF & Email